Trial Information

Identification of Biomarkers Predicting Responsiveness to Rituximab in Follicular Lymphoma

OBJECTIVES:

- Correlate immunoglobulin Fc receptor (FcγR) polymorphisms with response, response
duration, and time to resistance in samples from patients with follicular lymphoma (FL)
treated with single-agent rituximab on ECOG-E4402.

- Identify gene expression profiles that correlate with response, response duration, and
time to rituximab resistance in these patients.

- Determine whether the FL microenvironment is predictive of initial response and
duration of response to rituximab.

OUTLINE: DNA and RNA from banked peripheral blood mononuclear cells (PBMCs) and
formalin-fixed paraffin-embedded (FFPE) tumor samples are analyzed for
immunoglobulin-receptor polymorphism, gene expression profile, and follicular lymphoma
microenvironment by real-time PCR, microarray hybridization, and IHC.

PROJECTED ACCRUAL: A total of 259 PBMC samples and 300 FFPE blocks will be accrued for this
study.